首页> 外文会议>World biomaterials congress >Development of an arterial flow assay for validation of targeting strategies with microparticles
【24h】

Development of an arterial flow assay for validation of targeting strategies with microparticles

机译:开发用于验证微粒靶向策略的动脉血流分析

获取原文

摘要

Introduction: Rupture of atherosclerotic plaques causes acute clinical events, such as ischemic stroke and myocardial infarct. Information about cellular activation appears to be highly relevant for predicting plaque evolution to rupture. P-selectin expressed by activated platelets and endothelial cells is upregulated in unstable plaques. Nano and microsystems targeted towards P-selectin have been developed for the diagnosis of cardiovascular diseases. In particular, fucoidan-based systems were shown to detect platelet and endothelial activation in vivo. However prior to in vivo evaluation, there is a need to analyze in vitro the interactions of such systems with their molecular targets. In addition to published techniques, such as flow cytometry and interaction studies with P-selectin at low shear stress, we developed a method to visualize and quantify the affinity of fucoidan-coated microparticles for recombinant P-selectin and for human activated platelet aggregates expressing P-selectin in arterial flow conditions. Materials and Methods: Fluorescent polymer microparticles (MPs) were synthesized by anionic emulsion polymerization and tested as model systems. Fucoidan coated MPs (Fuco-MPs) and control MPs (Control-MPs) were injected in channels of Vena8 Fluoro+ chambers (Cellix Ltd) coated with either recombinant P-, E- or L-selectin. ExiGo pump (Cellix Ltd) was used to generate arterial flow conditions (shear stress 67.5 dyne/cm~2). MPs adhesion was visualized and quantified in real time under fluorescence microscopy. A second set of experiments consisted first in injecting human whole blood into collagen coated channels to induce platelets activation and aggregation. Fuco-MPs or Control-MPs were then injected in the channels and their adhesion onto platelet aggregates was recorded. Results and Discussion: Fuco-MPs bound significantly more to the P-selectin coating than Control-MPs (p<0.01). Fuco-MPs adhered immediately after injection in a P-selectin dose-dependent manner. Furthermore, their adhesion to L- and E-selectins was significantly lower than to P-selectin (p<0.01). These results are encouraging as regards to the sensitivity and selectivity of Fuco-MPs, confirming fucoidan potential for active targeting. Moreover, only MPs coated with fucoidan accumulated at the surface of platelet aggregates. Fuco-MPs appear promising for therapeutic and diagnostic targeted delivery. Conclusion: A model was set up to mimic microparticles adhesion on P-selectin that is expressed on platelet aggregates occurring in thrombus formation. It could be used routinely to validate the targeting efficacy of other microsystems before their in vivo evaluation. Future developments include the implementation of a layer of activated endothelial cells. By offering a robust and tunable model of vascular wall lesions, this work participates in the development of personalized therapy and diagnosis in the cardiovascular field.
机译:简介:动脉粥样硬化斑块破裂会引起急性临床事件,例如缺血性中风和心肌梗塞。有关细胞活化的信息似乎与预测斑块破裂的破裂高度相关。由活化的血小板和内皮细胞表达的P-选择素在不稳定斑块中上调。针对P-选择蛋白的纳米系统和微系统已经开发出来,可用于诊断心血管疾病。特别是,基于岩藻依聚糖的系统已显示可在体内检测血小板和内皮细胞的活化。然而,在体内评估之前,需要在体外​​分析此类系统与其分子靶标的相互作用。除了已发布的技术(例如流式细胞术和在低剪切应力下与P-选择素的相互作用研究)以外,我们还开发了一种方法来可视化和定量岩藻依聚糖包被的微粒对重组P-选择素和表达P的人类活化血小板聚集体的亲和力-选择素在动脉血流情况下。材料与方法:通过阴离子乳液聚合合成了荧光聚合物微粒(MPs),并作为模型系统进行了测试。将Fucoidan包被的MPs(Fuco-MPs)和对照MPs(Control-MPs)注入涂覆有重组P-,E-或L-选择素的Vena8 Fluoro +室(Cellix Ltd)的通道中。使用ExiGo泵(Cellix Ltd)生成动脉血流状况(剪切应力为67.5达因/ cm〜2)。在荧光显微镜下实时观察和定量MPs的粘附。第二组实验包括首先将人全血注入胶原蛋白包被的通道中,以诱导血小板活化和聚集。然后将Fuco-MP或Control-MP注入通道中,并记录其在血小板聚集体上的附着力。结果与讨论:Fuco-MP与P-选择素涂层的结合比对照MPs多得多(p <0.01)。 Fuco-MPs在注射后立即以P-选择素剂量依赖性方式粘附。此外,它们对L-选择素和E-选择素的粘附力显着低于对P-选择素的粘附力(p <0.01)。关于Fuco-MP的敏感性和选择性,这些结果令人鼓舞,证实了岩藻依聚糖具有主动靶向的潜力。此外,仅用岩藻依聚糖包被的MP积聚在血小板聚集体的表面。 Fuco-MP似乎有望用于治疗性和诊断性靶向递送。结论:建立了一个模型来模拟P-选择素上的微粒粘附,该模型在血栓形成过程中出现的血小板聚集体上表达。在对其进行体内评估之前,可以常规地使用它来验证其他微系统的靶向功效。未来的发展包括活化内皮细胞层的实施。通过提供健壮且可调的血管壁病变模型,这项工作参与了心血管领域个性化治疗和诊断的开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号